Rotigaptide (ZP123) prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogs

JK Hennan, RE Swillo, GA Morgan, JC Keith… - … of Pharmacology and …, 2006 - ASPET
The antiarrhythmic and cardioprotective effect of increasing gap junction intercellular
communication during ischemia/reperfusion injury has not been studied. The antiarrhythmic …

The gap junction modifier, GAP-134 [(2S, 4R)-1-(2-aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic acid], improves conduction and reduces atrial fibrillation/flutter …

EI Rossman, K Liu, GA Morgan, RE Swillo… - … of Pharmacology and …, 2009 - ASPET
Gap junction uncoupling can alter conduction pathways and promote cardiac re-entry
mechanisms that potentiate many supraventricular arrhythmias, such as atrial fibrillation (AF) and …

Discovery of (2S,4R)-1-(2-Aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic Acid Hydrochloride (GAP-134)13, an Orally Active Small Molecule Gap-Junction …

…, E Kerns, L Di, A Alimardanov, RE Swillo… - Journal of medicinal …, 2009 - ACS Publications
Rotigaptide (3) is an antiarrhythmic peptide that improves cardiac conduction by modifying
gap-junction communication. Small molecule gap-junction modifiers with improved physical …

Evaluation of PAI-039 [{1-benzyl-5-[4-(trifluoromethoxy) phenyl]-1H-indol-3-yl}(oxo) acetic acid], a novel plasminogen activator inhibitor-1 inhibitor, in a canine model …

…, A Ji, GS Friedrichs, GA Morgan, RE Swillo… - … of Pharmacology and …, 2005 - ASPET
We tested a novel, orally active inhibitor of plasminogen activator inhibitor-1 (PAI-1) in a
canine model of electrolytic injury. Dogs received by oral gavage either vehicle (control) or the …

Pharmacologic inhibition of platelet vWF-GPIbα interaction prevents coronary artery thrombosis

JK Hennan, RE Swillo, GA Morgan… - Thrombosis and …, 2006 - thieme-connect.com
Under high shear arterial blood flow von Willebrand Factor (vWF) binds the platelet receptor
glycoprotein (GP) Ibα, leading to platelet adhesion, activation and thrombosis. Blockade of …

Sphingosine modulates myocyte electrophysiology, induces negative inotropy, and decreases survival after myocardial ischemia

GS Friedrichs, RE Swillo, B Jow, T Bridal… - Journal of …, 2002 - journals.lww.com
Contractility studies in isolated feline myocytes have demonstrated that sphingosine, a
metabolite stimulated by tumor necrosis factor (TNF) binding, decreases intracellular calcium …

GAP-134 ([2S, 4R]-1-[2-aminoacetyl] 4-benzamidopyrrolidine-2-carboxylic acid) prevents spontaneous ventricular arrhythmias and reduces infarct size during …

JK Hennan, RE Swillo, GA Morgan… - Journal of …, 2009 - journals.sagepub.com
The antiarrhythmic dipeptide, GAP-134, ([2S,4R]-1[2-aminoacetyl]-4-benzamido-pyrrolidine-2-carboxylic
acid) was evaluated in canine ischemia/reperfusion model. In dogs subjected to …

WAY-140312 reduces plasma PAI-1 while maintaining normal platelet aggregation

…, TM Antrilli, JS Bauer, GA Morgan, RE Swillo - Biochemical and …, 2003 - Elsevier
Plasminogen activator inhibitor-1 (PAI-1) is the major physiological inhibitor of tissue
plasminogen activator (tPA) and is elevated in diseases of vascular remodeling. In this study, we …

Effect of timing of treatment of the glyburide-reversible cardioprotective activity of BMS-180448

AW Gomoll, RA Roth, RE Swillo, AJ Baird… - … of Pharmacology and …, 1997 - ASPET
The effect of the timing of treatment with the ATP-regulated potassium channel agonist BMS-180448
was evaluated in isolated rat heart and ferret models of ischemia and reperfusion. In …

Discovery of a class of potent gap-junction modifiers as novel antiarrhythmic agents

ELP Chekler, JA Butera, L Di, RE Swillo… - Bioorganic & medicinal …, 2009 - Elsevier
In an effort to discover potent, orally bioavailable compounds for the treatment of atrial
fibrillation (AF) and ventricular tachycardia (VT), we developed a class of gap-junction modifiers …